The MSL will work primarily with commercialized therapies for cardiovascular disease, as well as developmental compounds for neuroscience and oncology. This is an opportunity to develop expertise in the rapidly evolving area heart failure, and to call on and interact with some of the leading cardiovascular thought leaders in the world.